1
![OncoVista Innovative Therapies]()
![OncoVista Innovative Therapies]()
![OncoVista Innovative Therapies]()
OncoVista Innovative Therapies
Leadership team
Dr. Alexander L. Weis Ph.D. (Chairman, CEO, Pres, CFO, Principal Accounting Officer and Sec.)
Products/ Services
Biotechnology, Health Diagnostics, Therapeutics
Number of Employees
0 - 50
Headquarters
San Antonio, Texas, United States
Established
2004
Company Registration
SEC CIK number: 0001094847
Traded as
OTC Pink:OVIT
Overview
Location
Summary
OncoVista Innovative Therapies, Inc., a biopharmaceutical company, develops targeted anticancer therapies by utilizing tumor-associated biomarkers. The company's product candidates include Cordycepin (OVI-123), which is in Phase I/II clinical trials for the treatment of refractory TdT positive leukemias; and L-Nucleoside Conjugates (OVI-117) that is under pre-clinical development for the treatment of colon cancer. The company was founded in 2004 and is based in San Antonio, Texas.
History
Established in 2004, OncoVista Innovative Therapies has been developing leading-edge cancer treatments to fight diseases and improve the quality of life for patients. Our goal has been to offer innovative therapies that target the unique needs of patients suffering from cancer.
Mission
OncoVista Innovative Therapies is committed to providing cutting-edge treatments to help patients fight cancer, while working with stakeholders to ensure access and affordability to our products.
Vision
We envision a world in which our next generation of treatments can reduce suffering and improve quality of life for patients and their families.
Key Team
Dr. Alexander L. Weis Ph.D. (Chairman, CEO, Pres, CFO, Principal Accounting Officer and Sec.)
Recognition and Awards
OncoVista has been awarded numerous national awards for our cancer treatment innovations, including the American Society of Clinical Oncology’s Breakthrough Therapy Award in 2012 and the Frommer Award from the American Society of Hematology in 2009.
References
Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.
Leadership team
Dr. Alexander L. Weis Ph.D. (Chairman, CEO, Pres, CFO, Principal Accounting Officer and Sec.)
Products/ Services
Biotechnology, Health Diagnostics, Therapeutics
Number of Employees
0 - 50
Headquarters
San Antonio, Texas, United States
Established
2004
Company Registration
SEC CIK number: 0001094847
Traded as
OTC Pink:OVIT